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ABSTRACT
Introduction There is a paucity of data that can be used to 
guide the management of critically ill patients with COVID-19. 
In response, a research and data- sharing collaborative—The 
COVID-19 Critical Care Consortium—has been assembled 
to harness the cumulative experience of intensive care units 
(ICUs) worldwide. The resulting observational study provides 
a platform to rapidly disseminate detailed data and insights 
crucial to improving outcomes.
Methods and analysis This is an international, multicentre, 
observational study of patients with confirmed or suspected 
SARS- CoV-2 infection admitted to ICUs. This is an evolving, 
open- ended study that commenced on 1 January 2020 and 
currently includes >350 sites in over 48 countries. The study 
enrols patients at the time of ICU admission and follows them 
to the time of death, hospital discharge or 28 days post- ICU 
admission, whichever occurs last. Key data, collected via an 
electronic case report form devised in collaboration with the 
International Severe Acute Respiratory and Emerging Infection 
Consortium/Short Period Incidence Study of Severe Acute 
Respiratory Illness networks, include: patient demographic 
data and risk factors, clinical features, severity of illness and 
respiratory failure, need for non- invasive and/or mechanical 
ventilation and/or extracorporeal membrane oxygenation 
and associated complications, as well as data on adjunctive 
therapies.
Ethics and dissemination Local principal investigators 
will ensure that the study adheres to all relevant national 
regulations, and that the necessary approvals are in place 
before a site may contribute data. In jurisdictions where 
a waiver of consent is deemed insufficient, prospective, 
representative or retrospective consent will be obtained, as 
appropriate. A web- based dashboard has been developed to 
provide relevant data and descriptive statistics to international 
collaborators in real- time. It is anticipated that, following study 
completion, all de- identified data will be made open access.
Trial registration number ACTRN12620000421932 
(http:// anzctr. org. au/ ACTRN12620000421932. aspx).
INTRODUCTION
The world is currently witnessing a viral 
pandemic. Cases of atypical pneumonia first 
emerged in Wuhan, China, in December 
2019.1 Investigation has identified the cause 
as a novel betacoronavirus, ultimately named 
SARS- CoV-2.2 The virus, and the disease it 
causes—COVID-19—has since spread interna-
tionally. WHO declared the outbreak a ‘Public 
Health Emergency of International Concern’ 
on 30 January 2020, and a ‘pandemic’ on 12 
March 2020. There have now been >39 million 
confirmed infections globally, resulting in 1.1 
million deaths (as of 17 October 2020).3
SARS-CoV-2, COVID-19 and critical illness
The mortality rate of COVID-19 among patients 
admitted to the intensive care unit (ICU) has 
been reported around 30%4 and substantially 
Strengths and limitations of this study
 ► This protocol is of a pragmatic international, mul-
ticentre, observational clinical study of patients 
with confirmed or suspected SARS- CoV-2 infection 
admitted to intensive care units (ICUs) around the 
world.
 ► This is an evolving clinical registry, which will fa-
cilitate the characterisation of patients and their 
management and provide real- time information on 
associated characteristics and outcomes.
 ► These data will assist clinicians in deriving evidence- 
based practices for the care of critically ill patients 
infected by SARS- CoV-2.
 ► Patients will not receive identical treatments and 
care.
 ► While this will limit some aspects of data analysis, 
it will also give breadth to the scope of the inves-
tigation, as data on laboratory and patient charac-
teristics, interventions and adjunct therapies and 
outcomes will be available.
 ► This study relies on clinicians and support staff to 
accurately record data during a time of increased 
patient influx and ICU workload, raising concerns 
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higher for mechanically ventilated patients.5–9 Early data 
and clinical experience indicate that this is caused primarily 
by acute hypoxaemic respiratory failure (AHRF).10 11 These 
same data have also prompted some authors to suggest 
that the pathobiology of COVID-19- associated AHRF may 
differ from that of acute respiratory distress syndrome 
(ARDS).12 13 This assertion hinges on reports of patients 
with severe COVID-19- associated AHRF and high pulmo-
nary compliance, a presentation not thought to be typical of 
ARDS. Much has also been made of the high incidence of 
thromboembolic events in critically ill patients.14 15 However, 
many reports are limited by either small numbers of patients 
or by geographic restrictions. These fail to account for vari-
ations in practices or for the variations between countries in 
patient, systemic and organisational factors. Consequently, 
much of our current practice is driven by anecdotal cases or 
by limited case series.
Rationale for developing a worldwide registry of patients with 
COVID-19 admitted to ICUs
We aim to improve conclusions robustness regarding the 
management, interventions and treatment of critically- ill 
patients with COVID-19 around the world. We aim to 
do this by using combined data sets which detail a wide 
variety of patients entering the ICU at multiple stages 
of COVID-19 illness from diverse geographic locations. 
This ongoing research effort will aid in developing best 
practices based on evidence from a wide variety of ICUs 
throughout the world. This is especially important as 
there is currently a paucity of evidence- based guidelines 
and limited clinical resources globally. This data will also 
aid decision- making of clinicians working in healthcare 




This is an international, multicentre, prospective, observa-
tional study. The study protocol V.1.2.8 appears in online 
supplemental 1.
Study eligibility
The inclusion criteria are: (1) clinically suspected (as 
determined by attending physician) or laboratory- 
confirmed SARS- CoV-2 infection (by real- time PCR and/
or next- generation sequencing) and (2) admission to an 
ICU. Patients admitted to an ICU for a reason other than 
SARS- CoV-2 infection are excluded. In addition, patients 
who were recently diagnosed with SARS- CoV-2 infection 
and later admitted to the ICU for reasons not related to the 
SARS- CoV-2 infection will be excluded. Patients of all ages 
from infants through adults can be enrolled into the study.
Enrolment and participating sites
This study commenced on 1 January 2020. There is no 
fixed end date for the study. Currently, 350 centres are 
included, spanning 48 countries (online supplemental 
2), coordinated by regional leads and assistants (online 
supplemental 3) and the operating team at the coordi-
nating site (online supplemental 3). Co- enrolment with 
other studies, including interventional trials, is permitted.
Outcome measures
A summary of variables recorded by the study case report 
form (CRF) is presented in table 1.
Data collection
Data collection methods
Streamlined data collection instruments and procedures 
are used to minimise the workload at study centres. Data 
Table 1 Assessment schedule
Screening ICU admission Start MV Start ECMO Daily Outcomes
Eligibility criteria x         
Demographics x       
Comorbidities x       
Severity scoring x       
Symptoms x       
ABG and biochemistry x x x x
Respiratory support   x x x
Adjunctive therapies   x x x
ECMO parameters     x x
Pulmonary mechanics     x x
Microbiology       x
Blood transfusion       x
Length of stay         x
Survival         x
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can be collected and entered prospectively (preferred) 
or retrospectively dependent on the participating site’s 
resources. Data collection begins at the time of hospital 
admission using the International Severe Acute Respira-
tory and Emerging Infection Consortium (ISARIC) and 
Short Period Incidence Study of Severe Acute Respiratory 
Illness (SPRINT- SARI) data tools (https:// isaric. tghn. 
org/ COVID- 19- CRF/). Data collection for the COVID-19 
Critical Care Consortium (CCC) observational study 
commences at the time of a patient’s admission to an ICU, 
using a study- specific adaptation of the ISARIC/SPRINT- 
SARI COVID-19 CRF (online supplemental 4). Figure 1 
outlines the schedule of assessments used for patients 
included in the COVID-19 CCC study. De- identified 
study data are collected and managed using the REDCap 
electronic data capture tool hosted at the University of 
Oxford, UK.16 Data will not be used for any purpose 
other than those described in the study protocol. Each 
site’s principal investigator is responsible for ensuring 
data integrity. Regular written and web- based training 
is provided. In countries unable to upload data into a 
centralised database, the ability to retain a local database 
on a national server is available, with aggregated anony-
mised data exported centrally for analysis.
Interhospital transfer
If a patient is transferred from a facility participating 
in the COVID-19 CCC and ISARIC/SPRINT- SARI to 
another participating centre, the patient’s previously 
allocated unique identifier transfers with them. However, 
sites will not have access to study data collected outside 
their hospital. It is the responsibility of each hospital to 
enter data pertaining to their component of the patient’s 
hospital admission. If a patient is transferred to a non- 
participating hospital, there will be no further data collec-
tion. All sites will be asked to include a COVID-19 CCC 
and ISARIC/SPRINT- SARI study information sheet in 
any outgoing patient’s documentation.
Data management
Several procedures are in place to optimise data quality and 
completeness. These include: (1) a detailed data dictionary, 
(2) quality assurance within the data management system, 
(3) quality assurance of key variables within the CRF and 
(4) regular written and web- based training for local study 
investigators. A compendious CRF is fundamental to the 
success of this study. Extensive efforts have been made to 
limit data collection to essential variables. It is hoped that 
this will contribute to more complete data entry with a 
reduced burden on participating centres. Information 
that is not available to the investigator will not be treated as 
missing, and no assumptions will be made for missing data. 
An audit will be conducted on a randomly selected sample 
(approximately 5%) of cases. In- person site visits will not 
be feasible, given the nature of the study and pandemic. 
Substudy projects will be accessed via the main CRF plat-
form. Specific extensions will be used to collect additional 
variables, limiting the overall burden on data collectors, but 
allowing centres involved in sub- studies to enter data in the 
single REDCap format.
Data access
The coordinating team will have access to all collected data 
to assure integrity, provide oversight and conduct the main 
study analyses. Individual sites will have access to all the data 
they collect. A multinational steering committee (online 
supplemental 1) oversees registry operations worldwide and 
approves investigator- initiated or site- specific substudies, 
external requests for data and reviews suggestions by partic-
ipants. To date, several substudies have been initiated 
focusing on the impact of COVID-19 on the brain, heart, 
kidneys, management and risks of ECMO, coagulation and 
thrombosis risks and long- term effects, all involving multi-
centre participation. Once approval is obtained, relevant 
de- identified data will be made available. It is anticipated 
that, following study completion, all de- identified data will 
be made open access.
Figure 1 Schematic study overview. The figure shows in detail periods of data collection into the International Severe Acute 
Respiratory and Emerging Infection Consortium (ISARIC) case report form (dark blue), COVID-19 Critical Care Consortium 
(COVID-19 CCC) case report form (red) and for both case report forms (light blue). As shown, data for the COVID-19 CCC can 
be collected and entered prospectively (preferred) or retrospectively dependent on the participating site’s resources. The study 
ends at death, hospital discharge/transfer or 28 days, whichever occurs latest. ICU, intensive care unit; SPRINT- SARI, Short 
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Statistical considerations
Initial characterisation will be descriptive, including all 
eligible patients at participating centres enrolled within 
defined timeframes. Where analysis is hypothesis- driven, 
sample size calculations and power analysis (where appro-
priate) will depend on the specific outcome or end point 
under consideration and will be predefined. Results that 
aim to show an association or test a hypothesis will include 
95% CIs. These intervals and associated means will be 
interpreted in terms of their clinical and statistical signifi-
cance, and discussion may include whether a comparison 
is under- powered.
For discharge, mortality and length- of- stay outcomes, 
we will use a survival analysis with competing risks 
approach.17 We will graphically depict the risks of death 
and discharge over time using cumulative incidence 
plots. We will estimate which patient variables influence 
the risk of death and discharge using Cox regression, 
with separate models for death and discharge. In addi-
tion to Cox models, we will construct non- linear predic-
tive models for both outcomes using Random Forest 
models, which will be externally validated on a hold- out 
test set. Comparison of the predictive performance of 
both the Cox regression and Random Forest modelling 
approaches will be made using: (1) a Brier score,18 (2) 
area under the receiver operating characteristic curves 
using a two- sided DeLong test and (3) calibration plots, 
characterised by visual inspection and reporting of 
slope and intercept.18 For the Random Forest models, a 
Shapley Tree Explainer will be used to identify variables 
that are highly predictive of each outcome.19 This analysis 
will follow the Transparent Reporting of a Multivariable 
Prediction Model for Individual Prognosis or Diagnosis 
reporting guideline for prediction model development 
and validation.20
To show within- patient trends, we will plot continuous 
longitudinal variables over time using line plots. We 
will summarise each trend using daily averages and will 
estimate trends over time and the influence of patient 
variables using a linear mixed model with a random 
intercept per patient to control for repeated data. For 
binary variables, we will use panel bar charts to show the 
average change over time, and will model these variables 
using a generalised linear mixed model with a binomial 
distribution. A smooth estimation using cubic spline 
will be explored to estimate potential non- linear trends 
of the continuous longitudinal variables and binary 
variables.
Patient and public involvement in research
The data collection methodology of this study has been 
designed without patient or public input due to the 
urgent need for inclusion of prospective data from crit-
ically ill COVID-19. However, a consultative approach is 
planned via structured interviews, workshops and surveys 
to develop research questions, refine methods and ensure 
public voice helps to shape consumer- focused outcomes.
ETHICS AND DISSEMINATION
Ethical considerations
Chief investigators and the study management team are 
responsible for ensuring that the study is conducted 
in accordance with both the protocols, Declaration of 
Helsinki and the Principles of Good Clinical Practice. The 
study management team will continue to work with local 
principal investigators to ensure that the study adheres to 
all relevant national regulations, and that the necessary 
approvals are in place before a site may contribute data. 
The principal investigator at each site is responsible for 
maintaining a securely held enrolment log, linking each 
patient’s hospital record number with the COVID-19 CCC 
study number, if required. The original protocol and 
subsequent amendments will be translated into the main 
language of the collaborating institutions and submitted 
for institutional review board approval or an equivalent. 
Patients will not be enrolled under the conditions of an 
amended protocol, until after approval has been granted.
It is expected that this study will not require informed 
consent in most jurisdictions. This study is, in effect, 
a large- scale clinical audit, as all data are collected 
routinely. This may justify a waiver of consent. Any juris-
diction that deems informed consent necessary may use 
forms provided on our websites (https://www. elso. org/ 
COVID19/ ECMOCARD. aspx). Within such jurisdic-
tions, patients who meet the eligibility criteria will be 
approached directly. If this is not possible, due to the 
patient’s incapacity, a model of retrospective or represen-
tative consent may be used, per local requirements.
Dissemination
Due to the evolving nature of the pandemic and the 
uncertainty surrounding its impact, this study was 
designed to be responsive to the international call for 
swift characterisation of patients with COVID-19. Hence, 
in collaboration with University of Queensland and extra-
mural collaboration with IBM Australia (St. Leonard’s, 
Australia), a web- based dashboard has been developed to 
provide relevant data and descriptive statistics to interna-
tional collaborators in real- time. The collected data will 
also eventually be made available and shared on a public 
open access platform once core research questions have 
been answered.
DISCUSSION
Herein, we have described the rationale and design of 
an international, multicentre, observational registry 
of patients with COVID-19 admitted to an ICU. To 
date, the characterisation of patients admitted to ICUs 
with COVID-19 has been limited to national or single- 
centre series. This study, using a large collaborative 
network, attempts to overcome the limitations induced 
by small patient numbers and geographic restrictions, 
by providing real- time global data. In a pandemic of an 
emerging pathogen, high- quality, real- time information 
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response and cumulative experience of ICUs worldwide 
offer the best framework for determining evidence- based 
best practices and, therefore, improving outcomes for 
those requiring critical care.
The design of the COVID-19 CCC study has several 
strengths. First, the care of patients admitted to the ICU, 
specifically those who are mechanically ventilated, is 
dependent on regional resources and may vary.21 22 This 
potential heterogeneity is mitigated by the international 
composition of the consortium. In addition, we are plan-
ning to further characterise individual ICUs, collecting 
data on nurse/doctor- to- patient ratio, capacity and poten-
tial expanded capacity. Second, the study leverages novel 
data acquisition methods, which may improve and expe-
dite data collection. Third, the registry- based, collabora-
tive and open- source approach of the study lends itself to 
the conduct of multiple prospective substudies. Fourth, 
the study incorporates the provision of a web- based dash-
board, which provides real- time data in an accessible 
format.
Limitations
Patients will not receive identical treatments and care. 
While this will limit some aspects of data analysis, it will 
also give breadth to the scope of the investigation, as data 
on laboratory and patient characteristics, interventions 
and adjunct therapies, and outcomes will be available.
This study relies on clinicians and support staff to accu-
rately record data during a time of increased patient 
influx and ICU workload, raising concerns over data 
input error and completeness. To overcome this, coordi-
nators at each site have access to regular training, as well 
as ‘drop- in’ query sessions on- line.
This study will provide inclusive global characteri-
sation of critically ill patients with COVID-19. As the 
study is open- ended, continued data accrual will result 
in increased power to answer hypothesis- led questions 
over time and guide the development of evidence- based 
patient management tools to improve outcomes.
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